SK11832000A3 - Spsob separcie nekonvennch prenosnch pvodcov chorb z protenovho roztoku - Google Patents
Spsob separcie nekonvennch prenosnch pvodcov chorb z protenovho roztoku Download PDFInfo
- Publication number
- SK11832000A3 SK11832000A3 SK1183-2000A SK11832000A SK11832000A3 SK 11832000 A3 SK11832000 A3 SK 11832000A3 SK 11832000 A SK11832000 A SK 11832000A SK 11832000 A3 SK11832000 A3 SK 11832000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- adsorbent
- solution
- protein solution
- contamination
- hours
- Prior art date
Links
- 239000012460 protein solution Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 41
- 208000024777 Prion disease Diseases 0.000 title abstract description 6
- 231100000676 disease causative agent Toxicity 0.000 title abstract description 6
- 239000003463 adsorbent Substances 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000725 suspension Substances 0.000 claims abstract description 11
- 239000010451 perlite Substances 0.000 claims abstract description 9
- 235000019362 perlite Nutrition 0.000 claims abstract description 9
- 239000005909 Kieselgur Substances 0.000 claims abstract description 5
- 239000001913 cellulose Substances 0.000 claims abstract description 5
- 229920002678 cellulose Polymers 0.000 claims abstract description 5
- 229910000000 metal hydroxide Inorganic materials 0.000 claims abstract description 5
- 150000004692 metal hydroxides Chemical class 0.000 claims abstract description 5
- 239000000440 bentonite Substances 0.000 claims abstract description 4
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002734 clay mineral Substances 0.000 claims abstract description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 3
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 3
- 238000011109 contamination Methods 0.000 claims abstract 5
- 238000001914 filtration Methods 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 8
- 229910044991 metal oxide Inorganic materials 0.000 claims description 3
- 150000004706 metal oxides Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- SHFGJEQAOUMGJM-UHFFFAOYSA-N dialuminum dipotassium disodium dioxosilane iron(3+) oxocalcium oxomagnesium oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Al+3].[Al+3].[K+].[K+].[Fe+3].[Fe+3].O=[Mg].O=[Ca].O=[Si]=O SHFGJEQAOUMGJM-UHFFFAOYSA-N 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 229940024545 aluminum hydroxide Drugs 0.000 claims 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229960000869 magnesium oxide Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 239000010836 blood and blood product Substances 0.000 abstract description 4
- 229940125691 blood product Drugs 0.000 abstract description 3
- 239000002250 absorbent Substances 0.000 abstract 1
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000012678 infectious agent Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 11
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000010544 human prion disease Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000006877 Pituitary Hormones Human genes 0.000 description 2
- 108010047386 Pituitary Hormones Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241001440741 CHER virus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98810108A EP0937735B1 (en) | 1998-02-11 | 1998-02-11 | A method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions |
| PCT/EP1998/008166 WO1999041274A1 (en) | 1998-02-11 | 1998-12-14 | A method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK11832000A3 true SK11832000A3 (sk) | 2001-09-11 |
Family
ID=8235933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1183-2000A SK11832000A3 (sk) | 1998-02-11 | 1998-12-14 | Spsob separcie nekonvennch prenosnch pvodcov chorb z protenovho roztoku |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6407212B1 (ja) |
| EP (1) | EP0937735B1 (ja) |
| JP (1) | JP4259758B2 (ja) |
| CN (1) | CN1284963A (ja) |
| AT (1) | ATE233275T1 (ja) |
| AU (1) | AU742239B2 (ja) |
| CA (1) | CA2320190C (ja) |
| DE (1) | DE69811628T2 (ja) |
| DK (1) | DK0937735T3 (ja) |
| ES (1) | ES2193499T3 (ja) |
| HU (1) | HUP0100708A2 (ja) |
| NO (1) | NO20004029L (ja) |
| NZ (1) | NZ506055A (ja) |
| PL (1) | PL342002A1 (ja) |
| RU (1) | RU2204566C2 (ja) |
| SK (1) | SK11832000A3 (ja) |
| WO (1) | WO1999041274A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1144015B2 (en) * | 1999-01-19 | 2010-11-17 | Common Services Agency | Treating protein-containing liquids |
| WO2002063306A2 (en) * | 2001-01-16 | 2002-08-15 | Biotransplant, Inc. | Use of high density microparticles for removal of pathogens |
| US6743899B2 (en) | 2001-05-08 | 2004-06-01 | Serologicals Royalty Company | Process for inactivating prions in lipoproteins |
| US7625351B2 (en) * | 2003-09-10 | 2009-12-01 | Triosyn Holding, Inc. | System, method and apparatus for purifying biological fluids such as blood and constituents thereof |
| EP2734281A1 (en) * | 2011-07-20 | 2014-05-28 | Qiagen GmbH | Filtering devices comprising clay minerals |
| US10398585B2 (en) | 2013-05-30 | 2019-09-03 | Xtreme Orthopedics Llc | Shoulder and arm restraint |
| US11638656B2 (en) | 2012-12-31 | 2023-05-02 | Xtreme Orthopedics Llc | Shoulder and arm restraint |
| USD962450S1 (en) | 2013-05-30 | 2022-08-30 | Extreme Orthopedics Llc | Shoulder immobilizer pillow |
| DE102015210395A1 (de) | 2015-06-05 | 2016-12-08 | Technische Universität Dresden | Filtervorrichtung und ein Verfahren zur selektiven Abtrennung eines Analyten aus einer Flüssigkeit |
| TW201808312A (zh) * | 2016-05-09 | 2018-03-16 | 理研技術系統股份有限公司 | 減低異常型普立昂蛋白之感染力的方法及預防治療普立昂疾病用之醫藥組成物 |
| CN107090026B (zh) * | 2017-03-27 | 2021-06-25 | 武汉中原瑞德生物制品有限责任公司 | 利用硅藻土从血液制品中分离血浆蛋白的方法和系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651437A1 (fr) * | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
| EP0679405A1 (de) * | 1994-04-25 | 1995-11-02 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Abtrennung von Viren aus Proteinlösungen |
| AU731770B2 (en) * | 1996-03-15 | 2001-04-05 | Imedex | Process for removing unconventional transmissible agents from a protein solution |
| US5808011A (en) * | 1996-07-01 | 1998-09-15 | Biopure Corporation | Method for chromatographic removal of prions |
| US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
-
1998
- 1998-02-11 EP EP98810108A patent/EP0937735B1/en not_active Expired - Lifetime
- 1998-02-11 ES ES98810108T patent/ES2193499T3/es not_active Expired - Lifetime
- 1998-02-11 AT AT98810108T patent/ATE233275T1/de active
- 1998-02-11 DK DK98810108T patent/DK0937735T3/da active
- 1998-02-11 DE DE69811628T patent/DE69811628T2/de not_active Expired - Lifetime
- 1998-12-14 WO PCT/EP1998/008166 patent/WO1999041274A1/en not_active Application Discontinuation
- 1998-12-14 AU AU22726/99A patent/AU742239B2/en not_active Ceased
- 1998-12-14 HU HU0100708A patent/HUP0100708A2/hu unknown
- 1998-12-14 CN CN98813583A patent/CN1284963A/zh active Pending
- 1998-12-14 US US09/582,644 patent/US6407212B1/en not_active Expired - Lifetime
- 1998-12-14 RU RU2000123400/12A patent/RU2204566C2/ru not_active IP Right Cessation
- 1998-12-14 CA CA002320190A patent/CA2320190C/en not_active Expired - Lifetime
- 1998-12-14 PL PL98342002A patent/PL342002A1/xx not_active Application Discontinuation
- 1998-12-14 JP JP2000531465A patent/JP4259758B2/ja not_active Expired - Lifetime
- 1998-12-14 NZ NZ506055A patent/NZ506055A/xx not_active IP Right Cessation
- 1998-12-14 SK SK1183-2000A patent/SK11832000A3/sk unknown
-
2000
- 2000-08-10 NO NO20004029A patent/NO20004029L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004029D0 (no) | 2000-08-10 |
| JP4259758B2 (ja) | 2009-04-30 |
| CA2320190A1 (en) | 1999-08-19 |
| JP2002503672A (ja) | 2002-02-05 |
| ATE233275T1 (de) | 2003-03-15 |
| ES2193499T3 (es) | 2003-11-01 |
| NO20004029L (no) | 2000-10-09 |
| RU2204566C2 (ru) | 2003-05-20 |
| DE69811628T2 (de) | 2003-12-18 |
| EP0937735A1 (en) | 1999-08-25 |
| PL342002A1 (en) | 2001-05-07 |
| EP0937735B1 (en) | 2003-02-26 |
| AU2272699A (en) | 1999-08-30 |
| DE69811628D1 (de) | 2003-04-03 |
| CA2320190C (en) | 2008-04-22 |
| CN1284963A (zh) | 2001-02-21 |
| HUP0100708A2 (hu) | 2001-06-28 |
| NZ506055A (en) | 2002-09-27 |
| WO1999041274A1 (en) | 1999-08-19 |
| DK0937735T3 (da) | 2003-06-02 |
| AU742239B2 (en) | 2001-12-20 |
| US6407212B1 (en) | 2002-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6197207B1 (en) | Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products | |
| SK11832000A3 (sk) | Spsob separcie nekonvennch prenosnch pvodcov chorb z protenovho roztoku | |
| Wagner et al. | Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization | |
| SK287633B6 (sk) | Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi | |
| Burnouf et al. | Current strategies to prevent transmission of prions by human plasma derivatives | |
| JPH1028581A (ja) | ウイルス除去用の構造がはつきりしたデプスフイルター | |
| Kempf et al. | Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins | |
| AU2005265960B8 (en) | Process for improvement of virus-safe biological fluids | |
| US5696236A (en) | Method for the removal of viruses from protein solutions | |
| CZ20002613A3 (cs) | Způsob separace nekonvenčních přenosných původců chorob z roztoku proteinu | |
| AU774996B2 (en) | Treating protein-containing liquids | |
| US7252720B2 (en) | Removal of prion infectivity | |
| Burnouf et al. | Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms | |
| Segura et al. | Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom | |
| US5912328A (en) | Method for the removal of viruses from protein solutions | |
| Kim et al. | Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma | |
| JP2005139104A (ja) | プリオン蛋白質の分離・採取方法 | |
| Terrab et al. | Validation of a prion and virus purification process in the manufacture of bovine thrombin | |
| RU2223497C1 (ru) | Способ получения хламидийного антигена для реакции непрямой иммунофлуоресценции | |
| Contreras et al. | Infections Related to Red Cell Transfusions Including Variant Creutzfeldt‐Jakob Disease | |
| Willkommen | 1d Virus transmission by virus-inactivated plasma products | |
| US20050224355A1 (en) | Removal of biological contaminants |